Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry
- PMID: 38469689
- DOI: 10.1161/CIRCIMAGING.123.016143
Interaction of AI-Enabled Quantitative Coronary Plaque Volumes on Coronary CT Angiography, FFRCT, and Clinical Outcomes: A Retrospective Analysis of the ADVANCE Registry
Abstract
Background: Luminal stenosis, computed tomography-derived fractional-flow reserve (FFRCT), and high-risk plaque features on coronary computed tomography angiography are all known to be associated with adverse clinical outcomes. The interactions between these variables, patient outcomes, and quantitative plaque volumes have not been previously described.
Methods: Patients with coronary computed tomography angiography (n=4430) and one-year outcome data from the international ADVANCE (Assessing Diagnostic Value of Noninvasive FFRCT in Coronary Care) registry underwent artificial intelligence-enabled quantitative coronary plaque analysis. Optimal cutoffs for coronary total plaque volume and each plaque subtype were derived using receiver-operator characteristic curve analysis. The resulting plaque volumes were adjusted for age, sex, hypertension, smoking status, type 2 diabetes, hyperlipidemia, luminal stenosis, distal FFRCT, and translesional delta-FFRCT. Median plaque volumes and optimal cutoffs for these adjusted variables were compared with major adverse cardiac events, late revascularization, a composite of the two, and cardiovascular death and myocardial infarction.
Results: At one year, 55 patients (1.2%) had experienced major adverse cardiac events, and 123 (2.8%) had undergone late revascularization (>90 days). Following adjustment for age, sex, risk factors, stenosis, and FFRCT, total plaque volume above the receiver-operator characteristic curve-derived optimal cutoff (total plaque volume >564 mm3) was associated with the major adverse cardiac event/late revascularization composite (adjusted hazard ratio, 1.515 [95% CI, 1.093-2.099]; P=0.0126), and both components. Total percent atheroma volume greater than the optimal cutoff was associated with both major adverse cardiac event/late revascularization (total percent atheroma volume >24.4%; hazard ratio, 2.046 [95% CI, 1.474-2.839]; P<0.0001) and cardiovascular death/myocardial infarction (total percent atheroma volume >37.17%, hazard ratio, 4.53 [95% CI, 1.943-10.576]; P=0.0005). Calcified, noncalcified, and low-attenuation percentage atheroma volumes above the optimal cutoff were associated with all adverse outcomes, although this relationship was not maintained for cardiovascular death/myocardial infarction in analyses stratified by median plaque volumes.
Conclusions: Analysis of the ADVANCE registry using artificial intelligence-enabled quantitative plaque analysis shows that total plaque volume is associated with one-year adverse clinical events, with incremental predictive value over luminal stenosis or abnormal physiology by FFRCT.
Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02499679.
Keywords: artificial intelligence; atherosclerotic plaque; cardiac death; computed tomography angiography; coronary artery disease; major adverse cardiac events; myocardial infarction.
Conflict of interest statement
Dr Patel has received research grants from HeartFlow, Bayer, Janssen, and the National Heart, Lung, and Blood Institute; and has served on the advisory board for HeartFlow, Bayer, and Janssen. Dr Nørgaard has received unrestricted institutional research grants from Siemens and HeartFlow. Dr Fairbairn has served on the Speakers Bureau for HeartFlow. Dr Nieman has received institutional research support from Siemens Healthineers, HeartFlow, GE Healthcare, and Bayer Healthcare. Dr Hurwitz Koweek has received research support and speaking fees from HeartFlow and Siemens. Dr Pontone has received institutional research grant and honorarium as consultant/speaker from GE Healthcare, Bracco, Medtronic, Bayer, and HeartFlow. Dr Rabbat has served as a consultant for HeartFlow. Ms Mullen is an employee of and owns equity in HeartFlow. Dr De Bruyne has an institutional consulting relationship with Boston Scientific, Abbott Vascular, CathWorks, Siemens, GE Healthcare, and Coroventis Research; has received institutional research grants from Abbott Vascular, Coroventis Research, CathWorks, and Boston Scientific; and holds equities in Philips, Siemens, GE Healthcare, Edwards Lifesciences, HeartFlow, Opsens, and Celiad. Dr Rogers is employee of and owns equity in HeartFlow. Dr Leipsic has received an unrestricted research grant from GE Healthcare, has stock options and received consulting fees from HeartFlow and Circle CVI, and speaking fees from GE and Philips. Dr Ng is an employee of HeartFlow. The other authors report no conflicts.
Comment in
-
Prognostic Value of Coronary Atherosclerotic Burden, Its Plaque Components and Estimation of Coronary Flow by Coronary Computed Tomography.Circ Cardiovasc Imaging. 2024 Mar;17(3):e016524. doi: 10.1161/CIRCIMAGING.124.016524. Epub 2024 Mar 12. Circ Cardiovasc Imaging. 2024. PMID: 38469714 No abstract available.
Similar articles
-
AI-Quantitative CT Coronary Plaque Features Associate With a Higher Relative Risk in Women: CONFIRM2 Registry.Circ Cardiovasc Imaging. 2025 Jun;18(6):e018235. doi: 10.1161/CIRCIMAGING.125.018235. Epub 2025 Mar 31. Circ Cardiovasc Imaging. 2025. PMID: 40162910 Free PMC article.
-
Clinical Outcomes Based on Coronary Computed Tomography-Derived Fractional Flow Reserve and Plaque Characterization.JACC Cardiovasc Imaging. 2024 Mar;17(3):284-297. doi: 10.1016/j.jcmg.2023.07.013. Epub 2023 Sep 27. JACC Cardiovasc Imaging. 2024. PMID: 37768240
-
Coronary Computed Tomographic Angiography With Fractional Flow Reserve in Patients With Type 2 Myocardial Infarction.J Am Coll Cardiol. 2023 Oct 24;82(17):1676-1687. doi: 10.1016/j.jacc.2023.08.020. Epub 2023 Sep 29. J Am Coll Cardiol. 2023. PMID: 37777947
-
Plaque quantification from coronary computed tomography angiography in predicting cardiovascular events: A systematic review and meta-analysis.J Cardiovasc Comput Tomogr. 2025 Jul-Aug;19(4):423-432. doi: 10.1016/j.jcct.2025.05.003. Epub 2025 May 26. J Cardiovasc Comput Tomogr. 2025. PMID: 40425410
-
[Volume and health outcomes: evidence from systematic reviews and from evaluation of Italian hospital data].Epidemiol Prev. 2013 Mar-Jun;37(2-3 Suppl 2):1-100. Epidemiol Prev. 2013. PMID: 23851286 Italian.
Cited by
-
The Role of Cardiac Computed Tomography Angiography in Risk Stratification for Coronary Artery Disease.J Soc Cardiovasc Angiogr Interv. 2024 Nov 20;3(11):102230. doi: 10.1016/j.jscai.2024.102230. eCollection 2024 Nov. J Soc Cardiovasc Angiogr Interv. 2024. PMID: 39649823 Free PMC article. Review.
-
Coronary CT angiography evaluation with artificial intelligence for individualized medical treatment of atherosclerosis: a Consensus Statement from the QCI Study Group.Nat Rev Cardiol. 2025 Aug 1. doi: 10.1038/s41569-025-01191-6. Online ahead of print. Nat Rev Cardiol. 2025. PMID: 40751112 Review.
-
Impact of the recent advances in coronary artery disease imaging on pilot medical certification and aviation safety: current state and future perspective.Int J Cardiovasc Imaging. 2025 Jul;41(7):1249-1257. doi: 10.1007/s10554-025-03380-3. Epub 2025 May 7. Int J Cardiovasc Imaging. 2025. PMID: 40335830 Review.
-
Can Artificial Intelligence Help Us in the Evaluation of Coronary Artery Calcification Scores by Acting as a Prognosticator in Patients That Are Operated on Due to Non-Small Cell Lung Cancer? A Pivotal Study.J Clin Med. 2024 Nov 1;13(21):6579. doi: 10.3390/jcm13216579. J Clin Med. 2024. PMID: 39518718 Free PMC article.
-
Computed Tomography Angiography in the Catheterization Laboratory: A Guide Towards Optimizing Coronary Interventions.J Cardiovasc Dev Dis. 2025 Jan 16;12(1):28. doi: 10.3390/jcdd12010028. J Cardiovasc Dev Dis. 2025. PMID: 39852306 Free PMC article. Review.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical